Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Senior Vice President | December 14, 2011 | December 16, 2011 |
| ALIMERA SCIENCES INCALIM · Entity 11664 | Director | June 18, 2020 | June 22, 2020 |
| Absci CorpABSI · Entity 4685 | Director | June 30, 2026 | July 06, 2026 |
| Averin Capital Acquisition Corp.ACAAU · Entity 5761 | Director | February 18, 2026 | February 18, 2026 |
| Coherus Oncology, Inc.CHRS · Entity 6276 | Director | January 11, 2021 | January 13, 2021 |
| Kura Oncology, Inc.KURA · Entity 4871 | Director | June 04, 2026 | June 04, 2026 |
| NOVELION THERAPEUTICS INC.NVLN · Entity 152369 | Director · Chief Executive Officer | May 09, 2017 | May 11, 2017 |
| Omega Therapeutics, Inc.OMGA · Entity 83618 | Director | June 20, 2024 | June 21, 2024 |
| TriSalus Life Sciences, Inc.TLSI · Entity 5872 | Director · CEO and President | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date December 14, 2011 · Filed December 16, 2011
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 119,342 |
Ending reported balance
After 2011-12-14 transaction · row 27
27 source rows · reconciled sequenceRow 1 · 2011-12-14 · Exercise / conversion · Acquired 53,201 · Balance 172,543 Row 2 · 2011-12-14 · Sale · Disposed 500 · Balance 172,043 Row 3 · 2011-12-14 · Sale · Disposed 300 · Balance 171,743 Row 4 · 2011-12-14 · Sale · Disposed 2,500 · Balance 169,243 Row 5 · 2011-12-14 · Sale · Disposed 200 · Balance 169,043 Row 6 · 2011-12-14 · Sale · Disposed 100 · Balance 168,943 Row 7 · 2011-12-14 · Sale · Disposed 900 · Balance 168,043 Row 8 · 2011-12-14 · Sale · Disposed 1,550 · Balance 166,493 Row 9 · 2011-12-14 · Sale · Disposed 2,100 · Balance 164,393 Row 10 · 2011-12-14 · Sale · Disposed 2,100 · Balance 162,293 Row 11 · 2011-12-14 · Sale · Disposed 100 · Balance 162,193 Row 12 · 2011-12-14 · Sale · Disposed 900 · Balance 161,293 Row 13 · 2011-12-14 · Sale · Disposed 5,500 · Balance 155,793 Row 14 · 2011-12-14 · Sale · Disposed 5,195 · Balance 150,598 Row 15 · 2011-12-14 · Sale · Disposed 1,600 · Balance 148,998 Row 16 · 2011-12-14 · Sale · Disposed 100 · Balance 148,898 Row 17 · 2011-12-14 · Sale · Disposed 1,900 · Balance 146,998 Row 18 · 2011-12-14 · Sale · Disposed 3,700 · Balance 143,298 Row 19 · 2011-12-14 · Sale · Disposed 4,500 · Balance 138,798 Row 20 · 2011-12-14 · Sale · Disposed 2,300 · Balance 136,498 Row 21 · 2011-12-14 · Sale · Disposed 5,275 · Balance 131,223 Row 22 · 2011-12-14 · Sale · Disposed 2,488 · Balance 128,735 Row 23 · 2011-12-14 · Sale · Disposed 212 · Balance 128,523 Row 24 · 2011-12-14 · Sale · Disposed 2,700 · Balance 125,823 Row 25 · 2011-12-14 · Sale · Disposed 3,200 · Balance 122,623 Row 26 · 2011-12-14 · Sale · Disposed 2,781 · Balance 119,842 Row 27 · 2011-12-14 · Sale · Disposed 500 · Balance 119,342 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.63 · Expires 2012-02-14 | Direct | 0 |
Reported balance
After 2011-12-14 transaction · row 29
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 29 · 2011-12-14 · Exercise / conversion · Disposed 53,201 · Balance 0 F2: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 80 |
Reported balance
Holding disclosure · report date 2011-12-14 · row 28
Holding and transaction disclosures are not merged.
1 source rowRow 28 · Balance 80 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of December 14, 2011. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of December 14, 2011.
F2: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3.
ALIMERA SCIENCES INC
Report date June 18, 2020 · Filed June 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.70 · Expires 2030-06-17 | Direct | 3,333 |
Reported balance
After 2020-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-18 · Grant · Acquired 3,333 · Balance 3,333 F1: Vests in equal monthly installments over 12 months starting one month after the grant date (June 18, 2020), provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests in equal monthly installments over 12 months starting one month after the grant date (June 18, 2020), provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date.
Absci Corp
Report date June 30, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,300 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Purchase · Acquired 12,900 · Balance 21,300 F1: Open market purchase of shares in accordance with Issuer's trading policies. |
Filing footnotes · ownership attribution and instrument terms
F1: Open market purchase of shares in accordance with Issuer's trading policies.
Averin Capital Acquisition Corp.
Report date February 18, 2026 · Filed February 18, 2026
This filing explicitly reported no securities owned.
Coherus Oncology, Inc.
Report date January 11, 2021 · Filed January 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.58 · Expires 2031-01-11 | Direct | 20,000 |
Reported balance
After 2021-01-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-11 · Grant · Acquired 20,000 · Balance 20,000 F1: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Kura Oncology, Inc.
Report date June 04, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $8.77 · Expires 2036-06-03 | Direct | 35,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 35,000 · Balance 35,000 F1: This option vests in full on the one year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in full on the one year anniversary of the date of grant.
NOVELION THERAPEUTICS INC.
Report date May 09, 2017 · Filed May 11, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 6,632 |
Reported balance
After 2017-05-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-05-09 · Exercise / conversion · Acquired 6,632 · Balance 6,632 F1: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. F2: Each restricted stock unit represents a contingent right to receive one common share. |
| Common SharesSEC Table I · non-derivative | Direct | 4,384 |
Reported balance
After 2017-05-09 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2017-05-09 · Tax withholding · Disposed 2,248 · Balance 4,384 F3: The shares reported as disposed were withheld by the Issuer to satisfy tax withholding obligations of the Reporting Person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 13,264 |
Reported balance
After 2017-05-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-05-09 · Exercise / conversion · Disposed 6,632 · Balance 13,264 F2: Each restricted stock unit represents a contingent right to receive one common share. F1: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. F4: 33.34% of the grant vested on May 9, 2017. Subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or one of its affiliates, 33.33% of the grant will vest on May 9, 2018 and 33.33% of the grant will vest on May 9, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016.
F2: Each restricted stock unit represents a contingent right to receive one common share.
F3: The shares reported as disposed were withheld by the Issuer to satisfy tax withholding obligations of the Reporting Person.
F4: 33.34% of the grant vested on May 9, 2017. Subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or one of its affiliates, 33.33% of the grant will vest on May 9, 2018 and 33.33% of the grant will vest on May 9, 2019.
Omega Therapeutics, Inc.
Report date June 20, 2024 · Filed June 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.20 · Expires 2034-06-19 | Direct | 25,000 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 25,000 · Balance 25,000 F1: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.
TriSalus Life Sciences, Inc.
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,074,990 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Tax withholding · Disposed 2,693 · Balance 1,074,990 F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units previously granted. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units previously granted.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aegerion Pharmaceuticals, Inc.
Report date November 29, 2016 · Filed December 01, 2016
Section 16 reporting ended · disclosed 2016-12-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.65 · Expires 2026-01-07 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-11-29 · Disposition to issuer · Disposed 600,000 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective on November 29, 2016, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 (the "Exchange Ratio") by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc." ("Novelion"). F1: 25% of the shares of common stock underlying this stock option award were to vest on January 7, 2017. The remaining 75% of the shares of common stock underlying this stock option award were to vest thereafter in equal monthly installments through January 7, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.46 · Expires 2026-05-09 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-11-29 · Disposition to issuer · Disposed 194,000 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective on November 29, 2016, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 (the "Exchange Ratio") by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc." ("Novelion"). F3: 25% of the shares of common stock underlying this stock option award were to vest on May 9, 2017. The remaining 75% of the shares of common stock underlying this stock option award were to vest thereafter in equal monthly installments through May 9, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-11-29 · Disposition to issuer · Disposed 97,000 · Balance 0 F4: Each restricted stock unit represented a contingent right to receive one share of common stock. F6: Pursuant to the Merger Agreement, each restricted stock unit with respect to common stock of the Issuer ("Aegerion RSU") that was outstanding as of immediately prior to the effective time of the merger was exchanged for a restricted stock unit ("Novelion RSU") with respect to a number of common shares of Novelion equal to the product obtained by multiplying (i) the total number of shares of common stock of the Issuer subject to the Aegerion RSU immediately prior to the effective time of the merger by (ii) the Exchange Ratio. Each Novelion RSU is subject to the same terms and conditions applicable to the corresponding Aegerion RSU and the agreements evidencing grant of the Aegerion RSUs thereunder, including vesting terms, but excluding any terms that are rendered inoperative solely by reason of the merger. F5: The restricted stock units were to vest in three annual installments, with 33.34% of the units scheduled to vest on May 9, 2017, 33.33% of the units scheduled to vest on May 9, 2018 and 33.33% of the units scheduled to vest on May 9, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares of common stock underlying this stock option award were to vest on January 7, 2017. The remaining 75% of the shares of common stock underlying this stock option award were to vest thereafter in equal monthly installments through January 7, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.
F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective on November 29, 2016, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 (the "Exchange Ratio") by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc." ("Novelion").
F3: 25% of the shares of common stock underlying this stock option award were to vest on May 9, 2017. The remaining 75% of the shares of common stock underlying this stock option award were to vest thereafter in equal monthly installments through May 9, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.
F4: Each restricted stock unit represented a contingent right to receive one share of common stock.
F5: The restricted stock units were to vest in three annual installments, with 33.34% of the units scheduled to vest on May 9, 2017, 33.33% of the units scheduled to vest on May 9, 2018 and 33.33% of the units scheduled to vest on May 9, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.
F6: Pursuant to the Merger Agreement, each restricted stock unit with respect to common stock of the Issuer ("Aegerion RSU") that was outstanding as of immediately prior to the effective time of the merger was exchanged for a restricted stock unit ("Novelion RSU") with respect to a number of common shares of Novelion equal to the product obtained by multiplying (i) the total number of shares of common stock of the Issuer subject to the Aegerion RSU immediately prior to the effective time of the merger by (ii) the Exchange Ratio. Each Novelion RSU is subject to the same terms and conditions applicable to the corresponding Aegerion RSU and the agreements evidencing grant of the Aegerion RSUs thereunder, including vesting terms, but excluding any terms that are rendered inoperative solely by reason of the merger.
Prometheus Biosciences, Inc.
Report date June 16, 2023 · Filed June 16, 2023
Section 16 reporting ended · disclosed 2023-06-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 1
1 source rowRow 1 · 2023-06-16 · Disposition to issuer · Disposed 2,071 · Balance 0 F1: Reflects restricted stock units. F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.00 · Expires 2031-03-10 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-16 · Disposition to issuer · Disposed 40,000 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.02 · Expires 2032-05-18 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-16 · Disposition to issuer · Disposed 20,500 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects restricted stock units.
F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3)
F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2020 Filed Jun 24, 2020 20:55 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $12.37 | $0.00 |
DisclosureSEC source: 0001567619-20-012534 · doc1.xml · derivative · entry 7 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2029-01-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 20:55 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0001567619-20-012534 · doc1.xml · derivative · entry 6 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 20:55 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,997 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001567619-20-012534 · doc1.xml · derivative · entry 5 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,997 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 20:55 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 54,997 | $17.58 | $966,759.26 |
DisclosureSEC source: 0001567619-20-012534 · doc1.xml · nonDerivative · entry 4 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The transaction was executed in multiple trades in prices ranging from $17.43 to $17.71, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 20:55 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 20,000 | $12.37 | $247,400.00 |
DisclosureSEC source: 0001567619-20-012534 · doc1.xml · nonDerivative · entry 3 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 20:55 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 20,000 | $10.05 | $201,000.00 |
DisclosureSEC source: 0001567619-20-012534 · doc1.xml · nonDerivative · entry 2 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 20:55 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 14,997 | $2.50 | $37,500.00 |
DisclosureSEC source: 0001567619-20-012534 · doc1.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 20:18 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantStock Option (Right to Buy) · Derivative | 3,333 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001267602-20-000093 · wf-form4_159285712000024.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 3,333 shares Expires 2030-06-17 F1 · derivative.exercise_date: Vests in equal monthly installments over 12 months starting one month after the grant date (June 18, 2020), provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 22:54 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $17.73 | $0.00 |
DisclosureSEC source: 0001567619-20-001047 · doc1.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-10 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2020, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 20:10 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 13,000 | $0.00 Strike: $19.55 | $0.00 |
DisclosureSEC source: 0001209191-19-039245 · doc4.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-06-24 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 20:21 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001267602-19-000087 · wf-form4_156106209699552.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: Vests in equal monthly installments over 12 months starting one month after the grant date (June 19, 2019), provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| January 11, 2019 Filed Jan 30, 2019 21:08 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $12.37 | $0.00 |
DisclosureSEC source: 0000899243-19-002192 · doc4.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-01-11 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 11, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| November 06, 2018 Filed Nov 8, 2018 19:18 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 7,583 | $0.00 Strike: $11.55 | $0.00 |
DisclosureSEC source: 0001209191-18-057721 · doc4.xml · derivative · entry 2 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,583 Underlying: Common Stock · 7,583 shares Expires 2028-11-05 F2 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| November 06, 2018 Filed Nov 8, 2018 19:18 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 30,000 | $0.00 Strike: $11.55 | $0.00 |
DisclosureSEC source: 0001209191-18-057721 · doc4.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-11-05 F1 · derivative.exercise_date: This option vests in three equal annual installments commencing on the one year anniversary of the date of grant. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 20:31 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | GrantEmployee Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001267602-18-000087 · wf-form4_152961305232435.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-06-18 F1 · derivative.exercise_date: Exercisable in equal monthly installments over 12 months starting one month after the grant date, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:07 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0000899243-18-002889 · doc4.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-02-01 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| May 17, 2017 Filed May 19, 2017 20:06 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $23.80 | $0.00 |
DisclosureSEC source: 0000899243-17-013898 · doc4.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-17 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from May 17, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| May 09, 2017 Filed May 11, 2017 16:02 UTC | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | Exercise / conversionRestricted Stock Units · Derivative | 6,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-031894 · a4.xml · derivative · entry 3 Szela Mary T · CIK 0001410289 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,264 Underlying: Common Shares · 6,632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share. F1 · shares: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. F4 · derivative.exercise_date: 33.34% of the grant vested on May 9, 2017. Subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or one of its affiliates, 33.33% of the grant will vest on May 9, 2018 and 33.33% of the grant will vest on May 9, 2019. F4 · derivative.expiration_date: 33.34% of the grant vested on May 9, 2017. Subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or one of its affiliates, 33.33% of the grant will vest on May 9, 2018 and 33.33% of the grant will vest on May 9, 2019. F1 · derivative.underlying_shares: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. F1 · balance_after: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. Read SEC document |
| May 09, 2017 Filed May 11, 2017 16:02 UTC | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | Tax withholdingCommon Shares | 2,248 | $9.42 | $21,176.16 |
DisclosureSEC source: 0001104659-17-031894 · a4.xml · nonDerivative · entry 2 Szela Mary T · CIK 0001410289 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,384 F3 · shares: The shares reported as disposed were withheld by the Issuer to satisfy tax withholding obligations of the Reporting Person. Read SEC document |
| May 09, 2017 Filed May 11, 2017 16:02 UTC | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | Exercise / conversionCommon Shares | 6,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-031894 · a4.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. F2 · price: Each restricted stock unit represents a contingent right to receive one common share. F1 · balance_after: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. Read SEC document |
| December 22, 2016 Filed Dec 27, 2016 16:06 UTC | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | GrantStock Option (right to buy) · Derivative | 323,520 | $0.00 Strike: $8.65 | $0.00 |
DisclosureSEC source: 0001104659-16-163875 · a4.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,520 Underlying: Common Shares · 323,520 shares Expires 2026-12-22 F1 · derivative.exercise_price: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date. F2 · derivative.exercise_date: The common shares underlying this stock option award will vest in three equal installments on December 22, 2017, December 22, 2018 and December 22, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or one its affiliates. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 00:50 UTC | Aegerion Pharmaceuticals, Inc. AEGR · Entity 180735 | Disposition to issuerRestricted Stock Units · Derivative | 97,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-159826 · a4.xml · derivative · entry 3 Szela Mary T · CIK 0001410289 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 97,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represented a contingent right to receive one share of common stock. F6 · price: Pursuant to the Merger Agreement, each restricted stock unit with respect to common stock of the Issuer ("Aegerion RSU") that was outstanding as of immediately prior to the effective time of the merger was exchanged for a restricted stock unit ("Novelion RSU") with respect to a number of common shares of Novelion equal to the product obtained by multiplying (i) the total number of shares of common stock of the Issuer subject to the Aegerion RSU immediately prior to the effective time of the merger by (ii) the Exchange Ratio. Each Novelion RSU is subject to the same terms and conditions applicable to the corresponding Aegerion RSU and the agreements evidencing grant of the Aegerion RSUs thereunder, including vesting terms, but excluding any terms that are rendered inoperative solely by reason of the merger. F5 · derivative.exercise_date: The restricted stock units were to vest in three annual installments, with 33.34% of the units scheduled to vest on May 9, 2017, 33.33% of the units scheduled to vest on May 9, 2018 and 33.33% of the units scheduled to vest on May 9, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer. F5 · derivative.expiration_date: The restricted stock units were to vest in three annual installments, with 33.34% of the units scheduled to vest on May 9, 2017, 33.33% of the units scheduled to vest on May 9, 2018 and 33.33% of the units scheduled to vest on May 9, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 00:50 UTC | Aegerion Pharmaceuticals, Inc. AEGR · Entity 180735 | Disposition to issuerStock Option (Right to Buy) · Derivative | 194,000 | Not disclosed Strike: $2.46 | Not disclosed |
DisclosureSEC source: 0001104659-16-159826 · a4.xml · derivative · entry 2 Szela Mary T · CIK 0001410289 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 194,000 shares Expires 2026-05-09 F2 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective on November 29, 2016, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 (the "Exchange Ratio") by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc." ("Novelion"). F3 · derivative.exercise_date: 25% of the shares of common stock underlying this stock option award were to vest on May 9, 2017. The remaining 75% of the shares of common stock underlying this stock option award were to vest thereafter in equal monthly installments through May 9, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 00:50 UTC | Aegerion Pharmaceuticals, Inc. AEGR · Entity 180735 | Disposition to issuerStock Option (Right to Buy) · Derivative | 600,000 | Not disclosed Strike: $8.65 | Not disclosed |
DisclosureSEC source: 0001104659-16-159826 · a4.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600,000 shares Expires 2026-01-07 F2 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective on November 29, 2016, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 (the "Exchange Ratio") by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc." ("Novelion"). F1 · derivative.exercise_date: 25% of the shares of common stock underlying this stock option award were to vest on January 7, 2017. The remaining 75% of the shares of common stock underlying this stock option award were to vest thereafter in equal monthly installments through January 7, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 16:05 UTC | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | GrantRestricted Stock Units · Derivative | 99,483 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-160109 · a4.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,483 Underlying: Common Shares · 99,483 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share of the Issuer. F3 · price: Pursuant to the Agreement and Plan of Merger, dated as of June 14, 2016, by and among the Issuer, Aegerion Pharmaceuticals, Inc. ("Aegerion") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into Aegerion, effective on November 29, 2016, each restricted stock unit with respect to common stock of Aegerion ("Aegerion RSU") that was outstanding as of immediately prior to the effective time of the merger was exchanged for a restricted stock unit with respect to a number of common shares of the Issuer ("Issuer RSU") equal to the product obtained by multiplying (i) the total number of shares of common stock of Aegerion subject to the Aegerion RSU immediately prior to the effective time of the merger by (ii) the exchange ratio of 1.0256. F4 · price: Each Issuer RSU is subject to the same terms and conditions applicable to the corresponding Aegerion RSU and the agreements evidencing grant of the Aegerion RSUs thereunder, including vesting terms, but excluding any terms that are rendered inoperative solely by reason of the merger. F2 · derivative.exercise_date: The restricted stock units will vest in three annual installments, with 33.34% of the units vesting on May 9, 2017, 33.33% of the units vesting on May 9, 2018 and 33.33% of the units vesting on May 9, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or any of its subsidiaries. F2 · derivative.expiration_date: The restricted stock units will vest in three annual installments, with 33.34% of the units vesting on May 9, 2017, 33.33% of the units vesting on May 9, 2018 and 33.33% of the units vesting on May 9, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or any of its subsidiaries. Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 53,201 | $0.00 Strike: $53.63 | $0.00 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · derivative · entry 29 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 53,201 shares Expires 2012-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $54.46 | $27,230.00 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 27 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,342 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,781 | $54.45 | $151,411.55 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 26 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,842 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,200 | $54.44 | $174,208.00 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 25 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,623 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,700 | $54.43 | $146,961.00 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 24 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,823 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 212 | $54.43 | $11,538.10 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 23 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,523 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,488 | $54.42 | $135,396.96 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 22 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,735 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,275 | $54.41 | $287,012.75 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 21 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,223 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,300 | $54.41 | $125,131.50 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 20 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,498 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,500 | $54.40 | $244,800.00 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 19 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,798 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,700 | $54.40 | $201,261.50 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 18 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,298 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,900 | $54.39 | $103,341.00 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 17 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,998 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $54.39 | $5,438.75 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 16 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,898 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,600 | $54.39 | $87,016.00 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 15 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,998 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,195 | $54.38 | $282,504.10 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 14 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,598 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,500 | $54.38 | $299,062.50 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 13 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,793 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 900 | $54.37 | $48,933.00 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 12 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,293 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $54.37 | $5,436.50 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 11 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,193 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,100 | $54.36 | $114,156.00 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 10 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,293 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,100 | $54.36 | $114,145.50 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 9 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,393 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,550 | $54.35 | $84,242.50 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 8 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,493 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 900 | $54.35 | $48,910.50 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 7 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,043 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $54.34 | $5,434.00 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 6 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,943 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $54.34 | $10,867.00 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 5 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,043 Read SEC document |
| December 14, 2011 Filed Dec 16, 2011 23:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,500 | $54.33 | $135,825.00 |
DisclosureSEC source: 0001179110-11-016829 · edgar.xml · nonDerivative · entry 4 Szela Mary T · CIK 0001410289 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,243 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.